Pressure Matters: New Therapies in the Medical Management of Glaucoma (Archived CE Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
This case-based educational activity focuses on reinforcing the role of nitric oxide (NO) in glaucomatous eyes; achieving target intraocular pressure (IOP) levels; targeting new sites of action, such as the trabecular meshwork, with emerging therapies; and interpreting clinically relevant data supporting a role for emerging medical therapies in patients with glaucoma.
This educational activity is intended for optometrists.
Upon completion of this activity, participants will be better able to:
- Describe how NO lowers IOP through the trabecular meshwork
- Recognize the relationship between aqueous humor dynamics and selection of therapies to lower IOP in patients with glaucoma
- Develop evidence-based treatment plans for achieving target IOP levels in patients with glaucoma
- Employ patient counseling strategies to ensure adherence to IOP-lowering medication schedules
Michael Chaglasian, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grants/Research Support Recipient: Heidelberg Engineering, Inc; and Topcon Corporation; Advisory Board: Alcon; Allergan; and Bausch & Lomb Incorporated.
Murray Fingeret, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grants/Research Support Recipient: Carl Zeiss Meditec, Inc; Heidelberg Engineering, Inc; and Topcon Medical Systems, Inc; Consultant: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Diopsys, Inc; and Topcon Medical Systems, Inc.
Editorial Support Disclosures
The planners and staff of MedEdicus LLC have no relevant commercial relationships to disclose.
Tony Realini, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Inotek Pharmaceuticals Corporation; New World Medical, Inc; and Reichert, Inc.
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 59432-GL
COPE Course Category: Glaucoma
Product Usage in Accordance With Labeling
Please refer to the official prescribing information for each drug discussed in this activity for approved indications, contraindications, and warnings.
This continuing education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, Bausch & Lomb Incorporated, or Review of Optometry.
This CE activity is copyrighted to MedEdicus LLC ©2018. All rights reserved. 160D